Literature DB >> 25556664

Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles.

Souvik Biswas1, Scott H Medina1, Joseph J Barchi2.   

Abstract

The Thomsen Friedenreich antigen (TFag) disaccharide is a tumor-associated carbohydrate antigen (TACA) found primarily on carcinoma cells and rarely expressed in normal tissue. The TFag has been shown to interact with Galectin-3 (Gal-3), one in a family of β-galactoside binding proteins. Galectins have a variety of cellular functions, and Gal-3 has been shown to be the sole galectin with anti-apoptotic activity. We have previously prepared gold nanoparticles (AuNP) coated with the TFag in various presentations as potential anti-adhesive therapeutic tools or antitumor vaccine platforms. Here we describe the synthesis of TFag-glycoamino acid conjugates attached to gold nanoparticles through a combined alkane/PEG linker, where the TFag was attached to either a serine or threonine amino acid. Particles were fully characterized by a host of biophysical techniques, and along with a control particle carrying hydroxyl-terminated linker units, were evaluated in both Gal-3 positive and negative cell lines. We show that the particles bearing the saccharides selectively inhibited tumor cell growth of the Gal-3 positive cells significantly more than the Gal-3 negative cells. In addition, the threonine-attached TF particles were more potent than the serine-attached constructs. These results support the use of AuNP as antitumor therapeutic platforms, targeted against cell lines that express specific lectins that interact with TFag. Published by Elsevier Ltd.

Entities:  

Keywords:  Cytotoxicity; Galectin-3; Gold nanoparticles; Thomsen Friedenreich; Tumor-associated carbohydrate antigens

Mesh:

Substances:

Year:  2014        PMID: 25556664      PMCID: PMC4354769          DOI: 10.1016/j.carres.2014.11.002

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  78 in total

Review 1.  Possible functions of tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Curr Opin Immunol       Date:  1991-10       Impact factor: 7.486

2.  Divergent behavior of glycosylated threonine and serine derivatives in solid phase peptide synthesis.

Authors:  Yalong Zhang; Saddam M Muthana; Joseph J Barchi; Jeffrey C Gildersleeve
Journal:  Org Lett       Date:  2012-07-20       Impact factor: 6.005

Review 3.  Tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

4.  Highly efficient preparation of tumor antigen-containing glycopeptide building blocks from novel pentenyl glycosides.

Authors:  Serge A Svarovsky; Joseph J Barchi
Journal:  Carbohydr Res       Date:  2003-09-10       Impact factor: 2.104

5.  Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas.

Authors:  F Schneider; W Kemmner; W Haensch; G Franke; S Gretschel; U Karsten; P M Schlag
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

6.  Role of sialoglycan structures for the function of the epidermal growth factor receptor and the in vitro proliferation of head and neck cancer.

Authors:  W Bergler; A Stanek; F Riedel; G Petroianu; K Hörmann
Journal:  Eur Arch Otorhinolaryngol       Date:  1998       Impact factor: 2.503

7.  Serine versus threonine glycosylation: the methyl group causes a drastic alteration on the carbohydrate orientation and on the surrounding water shell.

Authors:  Francisco Corzana; Jesús H Busto; Gonzalo Jiménez-Osés; Marisa García de Luis; Juan L Asensio; Jesús Jiménez-Barbero; Jesús M Peregrina; Alberto Avenoza
Journal:  J Am Chem Soc       Date:  2007-07-07       Impact factor: 15.419

Review 8.  Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.

Authors:  S Hakomori
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

9.  GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells.

Authors:  Aurélie Cazet; Sophie Groux-Degroote; Béatrice Teylaert; Kyung-Min Kwon; Sylvain Lehoux; Christian Slomianny; Cheorl-Ho Kim; Xuefen Le Bourhis; Philippe Delannoy
Journal:  Biol Chem       Date:  2009-07       Impact factor: 3.915

10.  Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.

Authors:  Caroline B Madsen; Cecilie Petersen; Kirstine Lavrsen; Mikkel Harndahl; Søren Buus; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more
  6 in total

Review 1.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

Review 2.  Recent Advances in Subunit Vaccine Carriers.

Authors:  Abhishek Vartak; Steven J Sucheck
Journal:  Vaccines (Basel)       Date:  2016-04-19

Review 3.  Vaccine technologies: From whole organisms to rationally designed protein assemblies.

Authors:  Christopher P Karch; Peter Burkhard
Journal:  Biochem Pharmacol       Date:  2016-05-06       Impact factor: 5.858

4.  Immunological properties of gold nanoparticles.

Authors:  Lev A Dykman; Nikolai G Khlebtsov
Journal:  Chem Sci       Date:  2016-11-16       Impact factor: 9.825

Review 5.  Glyco-gold nanoparticles: synthesis and applications.

Authors:  Federica Compostella; Olimpia Pitirollo; Alessandro Silvestri; Laura Polito
Journal:  Beilstein J Org Chem       Date:  2017-05-24       Impact factor: 2.883

6.  A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.

Authors:  Kevin R Trabbic; Kristopher A Kleski; Joseph J Barchi
Journal:  ACS Bio Med Chem Au       Date:  2021-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.